Serum tests for colorectal cancer screening

Molecular Diagnosis and Therapy

Volumn 15, Issue 3, 2011, Pages 129-141

  Creeden, James ^a   Junker, Frank ^a   Vogel Ziebolz, Sabine ^b   Rex, Douglas ^c  

^a Roche Diagnostics Ltd   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Biomarkers; Colorectal cancer; Diagnostic tests; Screening.

Indexed keywords

ALBUMIN; ALPHA DEFENSIN; BARIUM; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 242 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CLUSTERIN; CYCLIN B1; EPIDERMAL GROWTH FACTOR RECEPTOR; FERRITIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 3; INTERLEUKIN 6; K RAS PROTEIN; MELANOMA ANTIGEN; OSTEOPONTIN; PROSTATE SPECIFIC ANTIGEN; SEPRASE; SURVIVIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR ANTIGEN; TUMOR MARKER;

ALBUMIN BLOOD LEVEL; BARIUM ENEMA; BLOOD SAMPLING; CANCER PATIENT; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST ENHANCEMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOCHEMISTRY; OCCULT BLOOD TEST; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIGMOIDOSCOPY; SYSTEMATIC REVIEW;

EID: 79960525947     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/bf03256403     Document Type: Review

References (103)

1. World Health Organization. Cancer [fact sheet no. 297]. Geneva: 2011 Feb [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs297/ en/index.html [Accessed 2011 Jun 1]
2. Power E,Miles A, vonWagner C, et al. Uptake of colorectal cancer screening: system, provider and individual factors and strategies to improve participation. Future Oncol 2009; 5 (9): 1371-88
3. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134 (5): 1570-95 (Pubitemid 351615355)
4. Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc 2006; 63 (4): 546-57
5. Sun L,Wu H, Guan YS. Colonography by CT, MRI and PET/CT combined with conventional colonoscopy in colorectal cancer screening and staging. World J Gastroenterol 2008; 14 (6): 853-63
6. Gollub MJ, Schwartz LH, Akhurst T. Update on colorectal cancer imaging. Radiol Clin North Am 2007; 45 (1): 85-118 (Pubitemid 44854041)
7. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [published erratum appears in Am J Gastroenterol 2009; 104 (6): 1613]. Am JGastroenterol 2009; 104 (3): 739-50
8. National Comprehensive Cancer Network [NCCN]. NCCN clinical practice guidelines in oncology: colorectal cancer screening. Fort Washington (PA): NCCN, 2009
9. Institute for Clinical Systems Improvement [ICSI]. Health care guideline: colorectal cancer screening. Bloomington (MN): ICSI, 2008
10. International Cancer ScreeningNetwork. Inventory of colorectal cancer screening activities in ICSN countries, May 2008 [online]. Available from URL: http://appliedresearch.cancer.gov/icsn/colorectal/screening.html [Accessed 2011 Jun 1]
11. Blom J. Screening and colorectal cancer. European Hospital 2010 Jan 26 [online]. Available from URL: http://www.european-hospital.com/en/ar ticle/6864-Screening-and-colorectal-cancer.html [Accessed 2011 Jun 1]
12. Cappell MS. From colonic polyps to colon cancer: pathophysiology, clinical presentation, screening and colonoscopic therapy. Minerva Gastroenterol Dietol 2007; 53 (4): 351-73 (Pubitemid 351169829)
13. Krier MJ, Pasricha PJ. Not your fathers colonoscopy: a high-tech future for screening and surveillance of colorectal cancer. Gastrointest Endosc Clin N Am 2008; 18 (3): 607-17, xi
14. Seifert B, Zavoral M, Fric P, et al. The role of primary care in colorectal cancer screening: experience from Czech Republic. Neoplasma 2008; 55 (1): 74-80
15. Malila N, Oivanen T, Hakama M. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme. Z Gastroenterol 2008; 46 Suppl. 1: S25-8 (Pubitemid 351548160)
16. Zorzi M, Barca A, Falcini F, et al. Screening for colorectal cancer in Italy: 2005 survey. Epidemiol Prev 2007; 31 (2-3 Suppl. 2): 49-60
17. Goulard H, Boussac-Zarebska M, Ancelle-Park R, et al. French colorectal cancer screening pilot programme: results of the first round. J Med Screen 2008; 15 (3): 143-8
18. Brotherstone H, Vance M, Edwards R, et al. Uptake of population-based flexible sigmoidoscopy screening for colorectal cancer: a nurse-led feasibility study. J Med Screen 2007; 14 (2): 76-80 (Pubitemid 47067761)
19. Australian Institute of Health and Welfare and the Australian Government Department of Health and Ageing for the National Bowel Cancer Screening Program. National Bowel Cancer Screening Program: annual monitoring report 2009. Canberra (ACT): Australian Institute of Health and Welfare, 2009 [online]. Available from URL: www.aihw.gov.au/WorkArea/Down loadAsset.aspx?id=6442454613 [Accessed 2011 Jun 28]
20. Forbes GM. Colorectal cancer screening tests: pros and cons, and for whom? Expert Rev Gastroenterol Hepatol 2008; 2 (2): 197-205
21. Forde KA. Colonoscopic screening for colon cancer. Surg Endosc 2006; 20 Suppl. 2: S471-4
22. Ackroyd FW.Complications of flexible endoscopy. In: Greene FL, Ponsky JL, editors. Endoscopic surgery. Philadelphia (PA): Saunders, 1994: 440-1
23. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale. Update based on new evidence. Gastroenterology 2003; 124 (2): 544-60 (Pubitemid 36169269)
24. Torres C, Szomstein S, Wexner SD. Virtual colonoscopy in colorectal cancer screening. Surg Innov 2007; 14 (1): 27-34 (Pubitemid 46563264)
25. Hara AK, Johnson CD, MacCarty RL, et al. Incidental extracolonic findings at CT colonography. Radiology 2000; 215 (2): 353-7 (Pubitemid 30237827)
26. Johnson CD, Dachman AH. CT colonography: the next colon screening examination? Radiology 2000; 216 (2): 331-41 (Pubitemid 30599846)
27. Fenlon HM, McAneny DB, Nunes DP, et al. Occlusive colon carcinoma: virtual colonoscopy in the preoperative evaluation of the proximal colon. Radiology 1999; 210 (2): 423-8 (Pubitemid 29055311)
28. Cappell MS. Reducing the incidence and mortality of colon cancer: mass screening and colonoscopic polypectomy. Gastroenterol Clin North Am 2008; 37 (1): 129-60, vii-viii (Pubitemid 351289023)
29. Virtual colonoscopy. Med Lett Drugs Ther 2005; 47 (1202): 15-6
30. Allison JE. Colon cancer screening guidelines 2005: the fecal occult blood test option has become a better FIT. Gastroenterology 2005; 129 (2): 745-8 (Pubitemid 41096658)
31. Allison JE, Lawson M. Screening tests for colorectal cancer: a menu of options remains relevant. Curr Oncol Rep 2006; 8 (6): 492-8 (Pubitemid 44697779)
32. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008; 299 (9): 1027-35 (Pubitemid 351347059)
33. Gupta AK, Brenner DE, Turgeon DK. Early detection of colon cancer: new tests on the horizon. Mol Diagn Ther 2008; 12 (2): 77-85 (Pubitemid 351570863)
34. World Gastroenterology Organisation [WGO]. Practice guidelines: colorectal cancer screening. Paris: WGO, 2007
35. Wang Q, Shen J, Li ZF, et al. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 2009; 19 (9): 287
36. Qiu Y, Patwa TH, Xu L, et al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res 2008; 7 (4): 1693-703
37. Habermann JK, Bader FG, Franke C, et al. From the genome to the proteome: biomarkers in colorectal cancer. Langenbecks Arch Surg 2008; 393 (1): 93-104 (Pubitemid 350196890)
38. Walgenbach-Brunagel G, Burger B, Leman ES, et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer. J Cell Biochem 2008; 104 (1): 286-94
39. Getzenberg RH, Schoen RE, Sokoll L, et al. Initial evaluation of colon cancerspecific antigen-2 (CCSA-2) as a serummarker for colorectal cancer [abstract no. 276]. 2008 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology; 2008 Jan 25-27; Orlando (FL) [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&conf ID=53&abstractID=10078 [Accessed 2011 Jun 1]
40. Leman ES, Schoen RE, Magheli A, et al. Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res 2008; 14 (5): 1349-54 (Pubitemid 351413914)
41. Leman ES, Schoen RE, Weissfeld JL, et al. Initial analyses of colon cancerspecific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007; 67 (12): 5600-5 (Pubitemid 46984988)
42. Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007; 11 (2): 235-44 (Pubitemid 46188816)
43. Abdel-Aziz MM, Lotfy M, El-Kady IM, et al. Mutant p53 protein in the serum of patients with colorectal cancer: correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor. Cancer Detect Prev 2009; 32 (4): 329-35
44. Chen Y, Lin P, Qiu S, et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 2007; 30 (5): 1137-44
45. Chen C, Chen LQ, Yang GL, et al. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases. Ai Zheng 2007; 26 (11): 1221-6
46. Mroczko B, Groblewska M, Wereszczynska-Siemiatkowska U, et al. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin Chim Acta 2006; 371 (1-2): 143-7 (Pubitemid 44162909)
47. Mroczko B, Szmitkowski M, Wereszczynska-Siemiatkowska U, et al. Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer. Int J Colorectal Dis 2007; 22 (1): 33-8 (Pubitemid 44742337)
48. Lee H, Rhee H, Kang HJ, et al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol 2008; 129 (5): 772-9
49. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008; 46 (10): 1423-8
50. Japink D, Leers MP, Sosef MN, et al. CEA in activated macrophages: new diagnostic possibilities for tumor markers in early colorectal cancer. Anticancer Res 2009; 29 (8): 3245-51
51. Shen C, Hu L, Xia L, et al. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol 2008; 38 (11): 770-6
52. Sorensen NM, Schrohl AS, Jensen V, et al. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer. Scand J Gastroenterol 2008; 43 (2): 186-91 (Pubitemid 351161530)
53. Pucci S, Bonanno E, Sesti F, et al. Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 2009; 104 (11): 2807-15
54. Coban S,Yuksel O, Kockar MC, et al. The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers. Hepatogastroenterology 2007; 54 (77): 1472-6 (Pubitemid 47203451)
55. Emara M, Cheung PY, Grabowski K, et al. Serum levels of matrix metalloproteinase- 2 and -9 and conventional tumor markers (CEA and CA 19-9) in patients with colorectal and gastric cancers. Clin Chem Lab Med 2009; 47 (8): 993-1000
56. Zheng GX, Wang CX, Qu X, et al. Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol 2006; 28 (4): 282-7 (Pubitemid 46226098)
57. de Noo ME, Mertens BJ, Ozalp A, et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 2006; 42 (8): 1068-76
58. Kim HJ, Yu MH, Kim H, et al. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 2008; 41 (10): 685-92
59. Xu Y, Zhao Z, Xiao Y, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer [abstract no. 1687]. 98th Annual Meeting, American Association for Cancer Research; 2007 Apr 14-18; Los Angeles (CA) [online]. Available from URL: http://www.aacrmeetingabstracts.org/cgi/ content/meeting-abstract/2007/1-Annual-Meeting/1687?maxtoshow= &hits=10&RESULTFORMAT=&author1=Xu&fulltext=colorectal& andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec= relevance&resourcetype=HWCIT [Accessed 2011 Jun 1]
60. Zhao Z, Xiao Y, Elson P, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol 2007; 25 (19): 2696-701 (Pubitemid 47123176)
61. Kumor A, Daniel P, Pietruczuk M, et al. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009; 24 (3): 275-81
62. DOnghia V, Leoncini R, Carli R, et al. Circulating gastrin and ghrelin levels in patients with colorectal cancer: correlation with tumour stage, Helicobacter pylori infection and BMI. Biomed Pharmacother 2007; 61 (2-3): 137-41 (Pubitemid 46561187)
63. Thomas SN, Tong Z, Stebe KJ, et al. Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology 2009; 46 (3): 207-25
64. Szajda SD, Borzym-KluczykM,Snarska J, et al. N-acetyl-beta-D- hexosaminidase and its isoenzymesAand B in blood serum and urine, as a potential colon cancer markers. Hepatogastroenterology 2009; 56 (94-95): 1287-98
65. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52 (6): 1062-9 (Pubitemid 43794418)
66. Lofton-Day C, Model F, Devos T, et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54 (2): 414-23 (Pubitemid 351302625)
67. Lofton-Day C, Model F, Devos T, et al. Clinical case-control study in plasma shows that the DNA methylation biomarker, septin 9, detects 70% of stage I-III colorectal cancer patients [abstract no. LB-165]. 98th Annual Meeting, American Association for Cancer Research; 2007 Apr 14-18; Los Angeles (CA) [online]. Available from URL: http://www.aacrmeetingabstracts.org/cgi/content/ meeting-abstract/2007/1-Annual-Meeting/LB-165?maxtoshow= &hits= 10&RESULTFORMAT=&author1=Model+F&andorexactfulltext= and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype= HWCIT [Accessed 2011 Jun 1]
68. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009 55 7 1337-46
69. Grutzmann R, Molnar B, Pilarsky C, et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One 2008; 3 (11): e3759
70. Nakayama G, Hibi K, Nakayama H, et al. A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients. Anticancer Res 2007; 27 (3B): 1459-63 (Pubitemid 46807223)
71. Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009; 15 (19): 6185-91
72. Lagoudianakis EE, Kataki A,Manouras A, et al. Detection of epithelial cells by RT-PCR targeting CEA, CK20, and TEM-8 in colorectal carcinoma patients using OncoQuick density gradient centrifugation system. J Surg Res 2009; 155 (2): 183-90
73. YehCS,Wang JY,WuCH, et al.Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by usingmembrane array with a multiple mRNA marker panel. Int J Oncol 2006; 28 (2): 411-20
74. Aslam MI, Taylor K, Pringle JH, et al. MicroRNAs are novel biomarkers of colorectal cancer. Br J Surg 2009; 96 (7): 702-10
75. ChajutA,KundelY, Levi Z, et al. Serum microRNAs as potential biomarkers for colorectal cancer [abstract no. 318]. 2009 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology; 2009 Jan 15-17; San Francisco (CA) [online]. Available from URL: http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=63&abstractID= 10353 [Accessed 2011 Jun 1]
76. Han M, Liew CT, Zhang HW, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin CancerRes 2008; 14 (2): 455-60 (Pubitemid 351226113)
77. Wang JY, Yeh CS, Chen YF, et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer. Int J Mol Med 2006; 17 (5): 737-47
78. Sastre J, Maestro ML, Puente J, et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann Oncol 2008; 19 (5): 935-8 (Pubitemid 351627310)
79. Giribaldi G, Procida S, Ulliers D, et al. Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method. J Mol Diagn 2006; 8 (1): 105-12 (Pubitemid 43257441)
80. Friederichs J, Gertler R, Rosenberg R, et al. Correlation of CK-20-positive cells in peripheral venous blood with serum CEA levels in patients with colorectal carcinoma. World J Surg 2007; 31 (12): 2329-34 (Pubitemid 350231467)
81. Findeisen P, RockelM,Nees M, et al. Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol 2008; 33 (5): 1001-10
82. Epigenomics AG. Ad hoc release pursuant to 15 WpHG (German Securities Trading Act): Epigenomics AG releases preliminary PRESEPT study data [media release]. 2010 Jan 15 [online]. Available from URL: http://www.epigenomics.com/ en/news-investors/news-media/ad-hoc-releases/2010/article/ad-hoc-mitteilung- nach-15-wphg-epigenomics-ag-veroeffentlicht-vorlaeufigepresept- studiendaten.html [Accessed 2011 Jun 1]
83. Flamini E, Mercatali L, Nanni O, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res 2006; 12 (23): 6985-8 (Pubitemid 44974493)
84. Ran Y, Hu H, Zhou Z, et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 2008; 14 (9): 2696-700
85. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996; 14 (10): 2843-77
86. Ahmed FE. Colorectal cancer epigenetics: the role of environmental factors and the search for molecular biomarkers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2007; 25 (2): 101-54 (Pubitemid 46897717)
87. SoreideK,Nedrebo BS, Knapp JC, et al. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol 2009; 18 (1): 31-50
88. Tsouma A, Aggeli C, Pissimissis N, et al. Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res 2008; 28 (6B): 3945-60
89. Lualdi M, Colombo A, Leo E, et al. Natural fluorescence spectroscopy of human blood plasma in the diagnosis of colorectal cancer: feasibility study and preliminary results. Tumori 2007; 93 (6): 567-71 (Pubitemid 351158067)
90. Leo E, Battaglia L, Colombo A, et al., editors. Natural fluorescence spectroscopy of human blood plasma for cancer detection: feasibility study and preliminary results [abstract no. 394]. 2008 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology; 2008 Jan 25-27; Orlando (FL) [online]. Available from URL: http://www.asco.org/ascov2/Meetings/Abstracts?vmview=abst- detail-view&abstractID=10280&confID=53 [Accessed 2011 Jun 1]
91. Chen C, Chen LQ, Yang GL, et al. The application of C12 biochip in the diagnosis and monitoring of colorectal cancer: systematic evaluation and suggestion for improvement. J Postgrad Med 2008; 54 (3): 186-90 (Pubitemid 352009157)
92. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9 (5): 709-16 (Pubitemid 27485301)
93. HoftmanAD,Tai LQ,Tze S, et al.MAGE-B2 autoantibody: a newbiomarker for pediatric systemic lupus erythematosus. J Rheumatol 2008; 35 (12): 2430-8
94. Wild N, Andres H, Rollinger W, et al. Early detection of colorectal cancer applying a combination of serum markers [abstract no. 2738]. 101st Annual Meeting, American Association for Cancer Research; 2010 Apr 17-21; Washington, DC [online]. Available from URL: http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey=aee42190-559d-4974-85ce-cb2815157 ce6&cKey=d4affd7e-dceb-4dc2-b53c-d6ad12a13471&mKey=%7b0591FA3 B-AFEF-49D2-8E65-55F41EE8117E%7d [Accessed 2011 Jun 1]
95. Aggarwal S, Birse C, Dhariwal G, et al. Colorectal cancer serum protein markers identified through mass spectrometry-based proteomic discovery platform [abstract no. 3545]. 100th Annual Meeting, American Association for Cancer Research; 2009 Apr 18-22; Denver (CO) [online]. Available from URL: http://www.aacrmeetingabstracts.org/cgi/content/meeting-abstract/2009/ 2-Annual-Meeting/3545?maxtoshow=&hits=10&RESULTFORMAT= &author1=Aggarwal&andorexactfulltext=and&searchid=1&FIRSTINDEX= 0&sortspec=relevance&resourcetype=HWCIT [Accessed 2011 Jun 1]
96. European Cancer Organisation. New blood tests promise simple, costeffective diagnosis of gastrointestinal cancers [media release]. 2009 Sep 21 [online]. Available from URL: http://www.ecco-org.eu/Conferences-and- Events/ECCO-15-ESMO-34/Press-Release/List-of-press-releases/New-bloodtests- promise-simple/page.aspx/1812 [Accessed 2011 Jun 1]
97. Bustin SA, Gyselman VG, Williams NS, et al. Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer 1999; 79 (11-12): 1813-20 (Pubitemid 29132310)
98. Schiedeck TH, Wellm C, Roblick UJ, et al. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis Colon Rectum 2003; 46 (6): 818-25 (Pubitemid 36693403)
99. Kaiser J. Biotechnology: researcher, two universities sued over validity of prostate cancer test. Science 2009; 325 (5947): 1484
100. Compton C, Fenoglio-Preiser CM, Pettigrew N, et al. American Joint Committee on Cancer prognostic factors consensus conference: Colorectal Working Group. Cancer 2000; 88 (7): 1739-57 (Pubitemid 30183160)
101. GeneNews Corporation. ColonSentry: every drop of blood tells a story [online]. Available fromURL: http://www.colonsentry.com/page.asp?id=9&name= ColonSentryOverview [Accessed 2011 Jun 1]
102. Xi L, Nicastri DG, El-Hefnawy T, et al. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 2007; 53 (7): 1206-15 (Pubitemid 47020975)
103. Lansdorp-Vogelaar I, van BM, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009; 101 (20): 1412-22